|Bid||0.0000 x 3100|
|Ask||0.0000 x 900|
|Day's Range||3.1450 - 3.3050|
|52 Week Range||2.7700 - 112.8700|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 08, 2022 - Aug 12, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.95|
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis i
Allakos Inc. (ALLK) closed at $3.86 in the latest trading session, marking a -1.03% move from the prior day.
In the latest trading session, Allakos Inc. (ALLK) closed at $5.46, marking a +0.18% move from the previous day.